- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Raj Chovatiya Discusses Safety, Efficacy, and Real-World Insights in Post-Approval Studies on Jak Inhibitors | AAD 2024
At the American Academy of Dermatology meeting in San Diego, Raj J. Chovatiya, M.D., Ph.D, discussed the evolution of studies on Jak inhibitors post-approval.
At the American Academy of Dermatology meeting in San Diego, Raj J. Chovatiya, M.D., Ph.D, discussed the evolution of studies on Jak inhibitors post-approval.
The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, shared the importance of long-term extension arms and innovative phase four designs to assess real-world outcomes.
It's notable to share that data from extended phase three studies showed no clear safety signals for box warning events, reassuring concerns raised at the launch.
Ongoing phase four studies are exploring lower Jak inhibitor doses and comparing their use to biologic therapies.
Registries are also providing insights into real-world efficacy and safety, contributing to increased comfort with Jak inhibitors over time.
The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, spoke in a session over the weekend at the American Academy Dermatology meeting about conditions that may mimic atopic dermatitis.
Read More
